Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

Author:

Annels Nicola E.,Mansfield David,Arif Mehreen,Ballesteros-Merino CarmenORCID,Simpson Guy R.,Denyer Mick,Sandhu Sarbjinder S.,Melcher Alan A.,Harrington Kevin J.,Davies Bronwyn,Au Gough,Grose Mark,Bagwan Izhar,Fox Bernard,Vile Richard,Mostafid Hugh,Shafren Darren,Pandha Hardev S.

Funder

Viralytics

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 90 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Vaccine approaches to treat urothelial cancer;Human Vaccines & Immunotherapeutics;2024-07-23

2. Exploring treatment options in cancer: tumor treatment strategies;Signal Transduction and Targeted Therapy;2024-07-17

3. Cancer therapy with the viral and bacterial pathogens: The past enemies can be considered the present allies;Life Sciences;2024-07

4. Oncolytic Viruses in Cancer Immunotherapy;Advanced Therapeutics;2024-05-22

5. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy;International Journal of Molecular Sciences;2024-04-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3